-
TNBC's new drug! The first TROP-2 target antibody-drug conjugate Trodelvy III phase: significantly extended survival!
Time of Update: 2020-07-15
, July 07, 2020 /PRNewswire/ -- Biovalley BIOON/ --- Immunomedics is a pioneer in the next generation of antibody drug conjugate (ADC) technology, dedicated to helping cancer patients change their
-
Cancer: Surprise discovery! Vitamin D makes immunotherapy safer! Significantly reduce the toxic side effects of immune checkpoints!
Time of Update: 2020-07-15
, July 7, 2020 / PRNewswire/ -- Taking vitamin D supplements may help prevent serious side effects that a revolutionary anti-cancer treatment can have The findings were published in cancer, a peer-
-
Her2 plus breast cancer heavy new drug! AstraZeneca/I-Sanantibodies-Drug Conjugate Enhertu EU Entry Review, Total Mitigation Rate 60.3%
Time of Update: 2020-07-15
, July 07, 2020 // Biovalley BIOON/--Daiichi Sankyo has announced that the European Medicines Agency (EMA) has accepted the of the new drug Enhertu (fam-trastuzumab deruxte), a new drug for breast
-
Cancer Res: Platelets can prevent cancer cell metastasis!
Time of Update: 2020-07-15
, July 6, 2020 /PRNewswire- bio-valley s/ scientists at Uppsala University have discovered a so-yet-unknown function of platelets in cancer In mouse models, these platelets have been shown to help
-
Nat Biomed Eng's new breakthrough! Systemic tracking of single cells with PET/CT imaging
Time of Update: 2020-07-15
, July 9, 2020 / Biovalley BIOON /- Living molecular imagery can detect the movement dynamics and movement of injected cells throughout the body, but most existing methods are unable to accurately a
-
FDA approves Roche's breast cancer dual-targeted HER2 antibody combination: patobead monoyduminal and querta-supra
Time of Update: 2020-07-14
U.S regulators have approved a fixed dose combination of Roche Phesgo (Pertuzumab, patozumab) and Herceptin (Trastuzumab, qural beadmonotagalyses) and hyaluronic acid asse for the treatment of early
-
Clini Cancer Research: Effects of ADT Joint Cy/GVAX Treatment on Microenvironment T-Cell Immersion of Prostate Tumors
Time of Update: 2020-07-14
BACKGROUND: Previous studies have shown that androgen deprivation therapy (ADT) promotes anti-tumor immunity in prostate cancer But it remains unclear whether a vaccine-based approach can amplify
-
Tisotumab Vedotin Treatment for Recurrent or Metastatic Cervical Cancer: Positive Results in Phase II Clinical Trials
Time of Update: 2020-07-14
The objective response rate to standard treatment in patients with recurrent or metastatic cervical cancer is usually less than 15%, with a median total survival of between 6.0 and 9.4 months Seattl
-
People are most afraid of sudden illness in middle age, and this rare tumor 'prefers' middle-aged people
Time of Update: 2020-07-14
People to middle-aged, often have old people, there are children, there are partners around, at this time the most afraid of illness And this is the true picture of 41-year-old Liu Lao Liu is from
-
Nat Commu: Colorectal near-end lymph node metastasis, from near to far?
Time of Update: 2020-07-14
Nature Communications published a research paper by the Center for Frontier Innovation in Biomedical Sciences (BIOPIC) at Peking University and the Bai Fan Group at the School of Life Sciences: Map
-
FDA approves oral drug for blood cancer - Low Methylation Agent Inqovi
Time of Update: 2020-07-14
Otsuka Pharmaceuticals inc announces the approval of Inqovi (decitabine/cedazuridine inhibitors/titabinin), for the treatment of myelogenmic abnormal syndrome (MDS) and chronic granulocytic mononucl
-
Lancet Oncology: New pathway stymied for DNA repair drugs combined with chemotherapy can suppress ovarian cancer
Time of Update: 2020-07-14
High-level slurry ovarian cancer (HGSOC) is the most common type of ovarian epithelial cancer, the degree of malignancy is high, prone to metastasis, so most patients are in the advanced stage of
-
PD-L1 single-resistant Bavencio, FDA approved for maintenance treatment for patients with late or metastatic urethra skin cancer
Time of Update: 2020-07-14
Merck and Pfizer announced that the U.S Food and Drug administration ( FDA ) has expanded its application range for the maintenance of local late or metastatic urinary tract cancer (UC) patients
-
ISA101b long peptide targets HPV16-positive cervical cancer, receives FDA-awarded orphan drug title
Time of Update: 2020-07-14
ISA Pharmaceuticals announced its main candidate, ISA101b, for the treatment of 16 type of human papillomavirus (HPV16) positive cervical cancer, and was awarded the title of "orphan drug" by the U.
-
Clini Cancer Research: Second generation ROS1-TKI, repotrectinib, anti-tumor activity of NSCLC for primary treatment or ROS1 mutation
Time of Update: 2020-07-14
Objective: Although the treatment of first-line keratosin has benefited patients with ROS1 and lung cancer, the incidence of ROS1-G2032R (ROS1G2032R) mutation and the progress of the central nervous
-
Nat BME: Methotrexate cell-derived microbubbles can relieve bile duct obstruction in patients with hepatic and extracellular bile duct cancer
Time of Update: 2020-07-14
Bile duct cancer is a type of epithelial malignant tumor, 5-year survival rate is particularly low, more than 90% of CAs from the hepatic bile duct, easy to form malignant bile duct obstruction Afte
-
BI-RADS (Mammogram Reporting and Data System) Hierarchical Interpretation
Time of Update: 2020-07-14
Many patients have completed breast-related examination, for the report list on the BI-RADS rating do not understand, today we will briefyou BI-RADS (Mammograms Reporting and Data System) is divide
-
PNAS: New breakthrough: Blocking a protein to suppress liver and bile duct cancer
Time of Update: 2020-07-14
Liver cancer is one of the most common digestive cancerinopathic cancer in China, about 110,000 people die of liver cancer every year, accounting for 45% of the world's liver cancer deaths Bile du
-
Keytruda in conjunction with Lenvima for liver cell carcinoma (HCC): Encountering Waterloo
Time of Update: 2020-07-14
Merck and Japan's Aoki corporation signed today that FDA issued a complete response letter to requests for accelerated approval of Keytruda and Lenvatinib for first-line treatment of patients with
-
Multidisciplinary diagnosis and treatment is most suitable for use in the field of cancer treatment, the earlier the application, the better!
Time of Update: 2020-07-14
" Although the World Health Organization has long defined cancer as a chronic disease, the fear of cancer remains deeply rooted, not only because of its high mortality rate, but also because of the h